FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Westphal Christoph H						2. Issuer Name and Ticker or Trading Symbol  TScan Therapeutics, Inc. [ TCRX ]								5. Relationship of Repor (Check all applicable) Director			10% C	wner	
	(First) (Middle) CAN THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 07/20/2021								Officer below)	(give title		Other below)	specify	
830 WINTER STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WALTH	AM M	IA	02451											X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(S	itate)	(Zip)																
		Ta	ble I - No	n-Der	rivativ	ve S	ecur	ities Ac	quired	, Dis	sposed o	of, or Be	eneficiall	y Owned					
			2. Transaction Date (Month/Day/Year)		ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dis			curities Acquired (A) or osed Of (D) (Instr. 3, 4 and		Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) c	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Voting Common Stock													914,	914,634		D			
Voting Common Stock													121,951		I		See footnote <sup>(1)</sup>		
Voting Common Stock			07/2	7/20/2021				С		1,145,5	05 A	(2)	1,145,505		1 1		See footnote <sup>(3)</sup>		
Voting Common Stock			07/2	7/20/2021				P		133,333	3 <sup>(4)</sup> A	\$15	1,278,838			1 1	See footnote <sup>(3)</sup>		
			Table II -								osed of converti			Owned					
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any				ransaction Code (Instr. )				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng d	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Series A Preferred Stock	(2)	07/20/2021			С			641,848	(2)		(2)	Voting Common Stock	641,848	(2)	0		I	See footnote <sup>(3)</sup>	
Series B Preferred Stock	(2)	07/20/2021			С			332,594	(2)		(2)	Voting Common Stock	332,594	(2)	0		I	See footnote <sup>(3)</sup>	
Series C Preferred Stock	(2)	07/20/2021			С			171,063	(2)	T	(2)	Voting Common Stock	171,063	(2)	0		I	See footnote <sup>(3)</sup>	

## **Explanation of Responses:**

- 1. These shares are held by the Reporting Person's spouse.
- 2. Each share of the Issuer's preferred stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date.
- 3. These shares are held by Longwood Fund IV, L.P. ("Longwood"). The general partner of Longwood is Longwood Fund IV GP, LLC ("Longwood GP"). Voting, investment and dispositive decisions at Longwood GP with respect to the securities held by Longwood are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood and as a result may be deemed to have beneficial ownership over such securities. Longwood GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood, except to the extent of their respective pecuniary interests therein.
- 4. Represents shares purchased in the Issuer's initial public offering.

## Remarks:

/s/ Christoph Westphal

07/22/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.